Advancing Ion Channels for Broad Discoveries
As a leader in ion channel drug discovery, Icagen has deep experience in advancing ion channel drug discovery programs alone and in collaboration with pharmaceutical and biotech partners. Icagen’s Ion Channel Technology platform allows progression of challenging ion channel targets by combining novel reagent generation, advanced biophysical analysis and cutting-edge applications of in silico drug discovery tools. The company also has similar depth for certain classes of transporter targets.
Through the acquisition of Icagen core assets, Ligand Pharmaceuticals Incorporated now benefits from the synergy that exists between Icagen’s Ion Channel Technology and other Ligand-owned technology platforms including the OmniAb® antibody discovery platform. Additionally, Icagen’s unique XRpro® technology, developed through refinements of X-ray fluorescence, advances ion channel and transporter drug discovery and development.
